Recipharm Introduces New Stand-Alone Service

November 20, 2019

The new service will assist pharmaceutical companies with quality control and analytical requirements.

Recipharm, a contract development and manufacturing organization (CDMO), launched its stand-alone service, Recipharm Analytical Solutions, at CPhI Worldwide on Nov. 5–7 in Frankfurt, Germany. The new service will assist pharmaceutical companies with quality control (QC) and analytical requirements, the company announced in a Nov. 4, 2019 press release.

The new service will offer method development services, method validation, and stability program design and implementation to analytical laboratories with resource challenges with the goal of reducing costs and timelines. The new service will also include specialist expertise in analytical techniques for in-vitro permeation testing and in-vitro release testing methods, and performance testing of inhalation products, extractables, and leachables.

“Many customers place their full stability programs with us, thus offloading their own QC labs, giving them capacity to focus on core activities,” said Dr. Ramesh Jagadeesan, director of Analytical Development at Recipharm, in the press release. “Our understanding of the entire drug development and manufacturing process delivers many benefits, including the ability to develop robust methods made for the stream-lined conditions within QC labs. We are used to working closely with formulation development teams with regulatory implications in mind. We also understand the logistics involved in the scale-up and tech transfer of a drug product, meaning transferring analytical methods should never be an issue.”

Users can access the new service through numerous contracts, including individual projects and fully dedicated laboratories.

Source: Recipharm